Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in The US: A Large Claims Data Analysis
source: Expert Review of Hematology
year: 2022
authors: Thokozeni Lipato, Ofelia Alvarez, Thomas Delea, et al.
summary/abstract:Sickle cell disease (SCD) is a genetic disease that impacts patients’ quality of life, healthcare costs, and life expectancy. Elevated sickle hemoglobin (HbS), which readily polymerizes, causes red blood cell sickling, leading to chronic hemolytic anemia and complications often requiring hospitalization and transfusions. In 2019, voxelotor, which inhibits HbS polymerization, was approved for SCD treatment.
Sickle cell disease (SCD) is a systemic, inherited disorder affecting approximately 100,000 people in the United States. It predominantly occurs in ethnic groups of African, Middle Eastern, South Mediterranean, and Indian descent. Mutations in the gene encoding hemoglobin (Hb) subunit β lead to sickle Hb (HbS), which then polymerizes under deoxygenated conditions and thereby disturbs red blood cell (RBC) shape. The consequences include the chronic destruction of RBCs, anemia, and limited oxygen delivery. This, in turn, can affect the function of various organs and increase the risk of morbidity, including disease progression and end-organ damage that can substantially impact the quality of life. Although mortality in children has decreased over time, mortality rates in adults have remained high over the past few decades. Characteristic effects of SCD are chronic anemia, hemolysis, and painful vaso-occlusive crises (VOCs). VOCs cause reoccurring episodes of severe pain and are often the main reason for patient hospitalizations
organization: Duke University, USA; VCU Health, USA; University of Miami, USA; Policy Analysis Inc., USA; Global Blood Therapeutics, USA
DOI: 10.1080/17474086.2022.2031967
read more
+myBinderRelated Content
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
-
Research Team Recognized for Organ-on-a-Chip DesignSCD is a group of genetic disorders that...
-
Christiana Care Sickle Cell ProgramChristiana Care is one of the country’...
-
Ginna Priola, MDGinna Priola is a pediatric hematologist...
-
Contrary to expectations: seasonal variation in sickle cell crisis – a nation wide data analysisBackground: Sickle cell crisis is a pain...
-
GBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
-
Fear, Anger, SCD and #BLACKLIVESMATTERJune 10, 2020 at 6pm Eastern Time Sessi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.